Skip to main content
Industry News
Study evaluates novel vest personalizing Lu-177 DOTATATE for NETs

A breakthrough vest with technology to personalize lutetium-177 DOTATATE among people with metastatic, somatostatin-receptor-2-positive neuroendocrine tumors developed by University of Washington researchers yielded similar or more precise organ-specific washout rates over seven days to 21 days, compared with three to four quantitative SPECT/CT images collected over a week, which is the current gold standard. The wearable technology was highlighted at the SNMMI Annual Meeting.

Full Story: